Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
TELA 
Tela Bio Inc (TELA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: TELA (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $5.6
1 Year Target Price $5.6
| 3 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -1.14% | Avg. Invested days 27 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 77.92M USD | Price to earnings Ratio - | 1Y Target Price 5.6 |
Price to earnings Ratio - | 1Y Target Price 5.6 | ||
Volume (30-day avg) 5 | Beta 0.79 | 52 Weeks Range 0.86 - 5.17 | Updated Date 06/30/2025 |
52 Weeks Range 0.86 - 5.17 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.35 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -61% | Operating Margin (TTM) -56.54% |
Management Effectiveness
Return on Assets (TTM) -33.34% | Return on Equity (TTM) -267.29% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 75315128 | Price to Sales(TTM) 1.09 |
Enterprise Value 75315128 | Price to Sales(TTM) 1.09 | ||
Enterprise Value to Revenue 1.06 | Enterprise Value to EBITDA -5.01 | Shares Outstanding 39555000 | Shares Floating 18664022 |
Shares Outstanding 39555000 | Shares Floating 18664022 | ||
Percent Insiders 8.31 | Percent Institutions 78.59 |
Analyst Ratings
Rating 3 | Target Price 5.6 | Buy 1 | Strong Buy 3 |
Buy 1 | Strong Buy 3 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Tela Bio Inc
Company Overview
History and Background
Tela Bio, Inc. was founded in 2012. The company focuses on developing and marketing regenerative tissue matrices for soft tissue reconstruction.
Core Business Areas
- Surgical Reconstruction: Develops and markets biologic scaffolds used in hernia repair, abdominal wall reconstruction, and plastic and reconstructive surgery.
Leadership and Structure
Antony Koblish is the President and CEO. The company has a board of directors with experience in the medical device industry.
Top Products and Market Share
Key Offerings
- OviTex PRS: OviTex PRS is used for Plastic and Reconstructive Surgery. Competitors include LifeCell (acquired by Allergan, now AbbVie), and other companies offering dermal matrices.
- OviTex Reinforced Tissue Matrix: OviTex is a reinforced tissue matrix used in hernia repair and abdominal wall reconstruction. It aims to provide strength and promote tissue regeneration. No precise market share information is available. Competitors include Allergan (now AbbVie) with its Strattice product, and BD (formerly C.R. Bard) with its Ventralight ST product.
Market Dynamics
Industry Overview
The surgical reconstruction market is growing due to an aging population and increasing demand for minimally invasive procedures.
Positioning
Tela Bio aims to differentiate itself through its focus on regenerative tissue matrices and its OviTex reinforced design which offers strength and facilitates tissue regeneration.
Total Addressable Market (TAM)
The total addressable market for soft tissue reconstruction is estimated to be billions of dollars. Tela Bio is positioned to capture a portion of this market through its product offerings, focusing on growing its market share within the larger reconstructive and regenerative medicine landscape.
Upturn SWOT Analysis
Strengths
- Proprietary OviTex technology
- Focus on regenerative medicine
- Experienced leadership team
Weaknesses
- Relatively small company compared to competitors
- Limited product portfolio
- Dependence on a few key products
Opportunities
- Expanding product portfolio
- Entering new markets
- Strategic partnerships and acquisitions
Threats
- Competition from larger companies
- Regulatory changes
- Pricing pressures
Competitors and Market Share
Key Competitors
- ABBV
- BDX
Competitive Landscape
Tela Bio competes with larger, established companies. Its advantages include its proprietary technology. Disadvantages include limited resources.
Growth Trajectory and Initiatives
Historical Growth: Historical growth trends are not available in this context.
Future Projections: Future projections are not available in this context.
Recent Initiatives: Recent strategic initiatives are not available in this context.
Summary
Tela Bio is a small company in a competitive market, banking on its proprietary technology. While the reconstructive surgery market is expanding, it faces challenges from industry giants. It will need strong execution and possible partnerships to gain significant market share. Its growth trajectory depends on successful commercialization and navigating regulatory hurdles.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
Disclaimers:
This analysis is based on publicly available information and does not constitute investment advice. Market share data are estimates and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Tela Bio Inc
Exchange NASDAQ | Headquaters Malvern, PA, United States | ||
IPO Launch date 2019-11-08 | Co-founder, CEO & Director Mr. Antony Koblish | ||
Sector Healthcare | Industry Medical Devices | Full time employees 209 | Website https://www.telabio.com |
Full time employees 209 | Website https://www.telabio.com | ||
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.